(Q35895921)

11 August 2017

title

Tertiary cytoreduction in patients with recurrent ovarian carcinoma (English)

1 reference

11 August 2017

4

Dennis S Chi

1 reference

11 August 2017

3

Richard R Barakat

1 reference

11 August 2017

Mario M Leitao

1

1 reference

11 August 2017

Steven Kardos

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

95

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

181-188

1 reference

11 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Identification of prognostic factors in advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Quality of complication reporting in the surgical literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.033

10.1016/J.YGYNO.2004.07.033

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference